Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Blueprint Medicines Corporation (BPMC) SEC filings, offering a regulatory view of the company’s evolution as a global biopharmaceutical business focused on allergy/inflammation and oncology/hematology. Through these documents, readers can review how Blueprint Medicines reports on its commercial activities with AYVAKIT/AYVAKYT (avapritinib), its pipeline programs in systemic mastocytosis and mast cell-mediated diseases, and its financial position.
Key filings for BPMC include annual reports on Form 10-K and quarterly reports on Form 10-Q, which historically have detailed product revenue from AYVAKIT/AYVAKYT, research and development expenses, selling, general and administrative expenses, and information about the company’s cash, cash equivalents and investments. Current reports on Form 8-K capture material events, such as the June 20, 2025 filing describing the company’s annual meeting of stockholders and voting results, and other significant corporate developments.
For corporate structure and trading status, a notable document is the Form 15 (15-12G) filed on July 28, 2025. In this filing, Blueprint Medicines certified the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record as of the certification date was one, reflecting the company’s transition following its acquisition agreement with Sanofi.
Investors researching BPMC SEC filings can use this page to locate historical 10-K and 10-Q reports for detailed financial and risk disclosures, Form 4 insider transaction reports where available, and 8-K filings describing governance matters and other material events. Stock Titan’s platform enhances this information with AI-powered summaries that explain the contents of lengthy filings, highlight key changes, and help users quickly identify items such as revenue trends, major agreements, capital structure changes and governance decisions. Real-time updates from EDGAR ensure that new BPMC-related filings, including acquisition-related documents and deregistration notices, are surfaced promptly with concise AI insights.
Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of 3,900,000 shares of Blueprint Medicines Corp common stock, representing 6.0% of the outstanding class based on 64,733,629 shares outstanding. The filing states the shares are directly held by the Pentwater Funds and that voting and dispositive power over these shares is shared (no sole voting or dispositive power reported). The Investment Manager is organized in Delaware and Mr. Halbower is a U.S. citizen; the business office for the reporting persons is 1001 10th Avenue South, Suite 216, Naples, FL. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control.
T. Rowe Price Associates, Inc. filed Amendment No. 9 to a Schedule 13G disclosing its holdings in Blueprint Medicines Corp common stock. The filing reports an aggregate beneficial ownership of 1,465,036 shares, representing 2.3% of the class, with sole voting power of 1,429,561 shares and sole dispositive power of 1,459,988 shares. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The form is signed by Ellen York, Vice President, dated 08/14/2025.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 375,000 shares of Blueprint Medicines Corp common stock, equal to 0.6% of the class based on 64,733,629 shares outstanding as reported by the issuer. The filing shows both reporting persons have sole voting power and sole dispositive power for the reported shares. Avoro is identified as an investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person; the shares are held for investment purposes on behalf of Avoro Life Sciences Fund LLC and are stated to be held in the ordinary course of business with no intent to change or influence control.